DOCSLIB.ORG

80Th Abstract Supplement Cover.Qxp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
80Th Abstract Supplement Cover.Qxp Abstracts of Posters Presented at the International Anesthesia Research Society 80th Clinical and Scientific Congress San Francisco, California March 24-28, 2006 This Supplement will Appear Online Only ISSN 0003-2999 Volume 102, Number 2S, February 2006 Supplement to Anesthesia & Analgesia ANESTHESIA & ANALGESIA Journal of the International Anesthesia Research Society, the Society of Cardiovascular Anesthesiologists, the Society for Pediatric Anesthesia, the Society for Ambulatory Anesthesia, the International Society for Anaesthetic Pharmacology, and the Society for Technology in Anesthesia IARS SCA SPA SAMBA ISAP STA Editor-in-Chief EDITORIAL BOARD Ronald D. Miller San Francisco, California John Butterworth Jerrold H. Levy Associate Editor-in-Chief Indianapolis, Indiana Atlanta, Georgia Cardiovascular Anesthesia Kenneth J. Tuman Neal Cohen Spencer S. Liu Chicago, Illinois San Francisco, California Seattle, Washington Assistant Associate Editor Pierre Coriat Hans-Joachim Priebe Cardiovascular Anesthesia Paris, France Charles W. Hogue, Jr. Freiburg, Germany Franc¸ois Donati St. Louis, Missouri Richard C. Prielipp Managing Editor Montre´al, Que´bec, Canada King C. Kryger Thomas J. Gal Minneapolis, Minnesota [email protected] Charlottesville, Virginia John C. Rowlingson Production Editor Tong J. Gan Charlottesville, Virginia Nancy Lynly Durham, North Carolina [email protected] Edward R. Sherwood Editorial Systems Manager Tony Gin Galveston, Texas Jeanette Esau Shatin, Hong Kong, China [email protected] Peter S. A. Glass Koh Shingu Guest Editors Stony Brook, New York Osaka, Japan Christian Apfel George M. Hall Elliott Bennett-Guerrero London, United Kingdom Peter Douglas Slinger Simon Body Toronto, Ontario, Canada James Caldwell Jonas S. Johansson Mark Chaney Philadelphia, Pennsylvania Mark H. Zornow Jacques Chelly Portland, Oregon Anthony Doufas Igor Kissin Marcel Durieux Boston, Massachusetts Kayser Enneking Pamela Flood Jeffrey Gross SECTION EDITORS Eugene Hessel Girish Joshi Ambulatory Anesthesia Pain Medicine Evan Kharasch Paul F. White Christoph Stein Tom Krejcie Dallas, Texas Berlin, Germany Harry Lemmens J. Lance Lichtor Anesthetic Pharmacology Martin London James G. Bovill Pediatric Anesthesia Robert McCarthy Leiden, The Netherlands Peter J. Davis Vance Nielsen Pittsburgh, Pennsylvania Christopher O’Connor Critical Care and Trauma Roger Royster Phillip Scuderi Jukka Takala Regional Anesthesia Bern, Switzerland John Sear Terese T. Horlocker Peter Sebel Economics, Education, and Rochester, Minnesota Stanton Shernan Linda Shore-Lesserson Health Systems Research Nikolaos Skubas Ronald D. Miller Technology, Computing, and Simulation James Sonner San Francisco, California Steven J. Barker Mark Stafford-Smith Greg Stratmann Neurosurgical Anesthesia Tucson, Arizona John Tetzlaff David S. Warner Meb Watcha Durham, North Carolina Book and Multimedia Reviews Denise Wedel Norig Ellison Charles Whitten Obstetric Anesthesia Hak Wong David J. Birnbach Philadelphia, Pennsylvania Paul Zanaboni Miami, Florida Manuscripts and editorial correspondence should be addressed to Ronald D. Miller, MD, Editor-in-Chief, ANESTHESIA & ANALGESIA, The Hearst Building, 5 Third Street, Suite 1216, San Francisco, CA 94103; telephone: (415) 777-2750; FAX: (415) 777-2803. Editorial Office E-Mail Address: [email protected]. For information concerning preparation of manuscripts, see “A Guide for Authors.” Books and multimedia for review should be sent directly to Norig Ellison, MD, Book Review Editor, Department of Anesthesia, University of Pennsylvania, Philadelphia, PA 19104. Society members should request issues or submit journal address changes to the IARS, 2 Summit Park Drive #140, Cleveland, OH 44131-2571; telephone: (216) 642-1124; FAX: (216) 642-1127; e-mail: [email protected]. The IARS website address is www.iars.org Non-members should request issues or submit address changes to Anesthesia & Analgesia, PO Box 1550, Hagerstown, MD 21741. Call (800) 638-3030; fax: (301) 223-2400; in Maryland, call collect (301) 223-2300. In Japan call: 81-3-5689-5400; fax: 81-3-5689-5402. In India call: 91-11-579-3211; fax: 91-11-579-8876. Classified advertisements should be placed with Lippincott Williams & Wilkins, Attn: Taron Butler; telephone: (800) 645-3658; FAX: (410) 528-4452. Permission requests, other than reproduction through the Copyright Clearance Center, should be directed to Copyright and Permissions Department, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436; telephone: (410) 528-4050. ANESTHESIA & ANALGESIA Journal of the International Anesthesia Research Society, the Society of Cardiovascular Anesthesiologists, the Society for Pediatric Anesthesia, the Society for Ambulatory Anesthesia, the International Society for Anaesthetic Pharmacology, and the Society for Technology in Anesthesia SOCIETY MEMBERSHIP INFORMATION: dues for 2006 are $50. All ISAP membership payments and corre- spondence should be sent to ISAP, Attn: Pamela R. Happ, Executive INTERNATIONAL ANESTHESIA RESEARCH Director ISAP, 2 Summit Park Drive, Suite 140, Cleveland, OH SOCIETY (IARS) is a nonprofit, scientific, and 44131-2571. Telephone (216) 447-7862; Fax (216) 642-1127; Web site: educational corporation. Membership dues include www.isaponline.org a reduced-rate subscription to ANESTHESIA & ANALGESIA and for 2006 are: world-wide $140 for SOCIETY FOR TECHNOLOGY IN ANESTHE- Members and $75 for Students. Residents/Fellows: see Joint SIA (STA) The Society for Technology in Anesthesia Resident/Fellow Membership information below. Member address is an international organization of physicians, en- changes, dues payments and correspondence should be sent to: gineers, students, and others with an interest in IARS, 2 Summit Park Drive, Suite 140, Cleveland, Ohio 44131- anesthesia-related technologies. Membership is 2571. Telephone (216) 642-1124; Fax (216) 642-1127; e-mail: open to all who are interested. The Society’s mission is to im- [email protected]; Web site: www.iars.org prove the quality of patient care by improving technology and its application. The Society promotes education and research, col- SOCIETY OF CARDIOVASCULAR ANESTHE- laborates with local, national, and international organizations, SIOLOGISTS (SCA) is a nonprofit, educational sponsors meetings and exhibitions, awards grants, and recog- foundation and is a recognized sub-specialty orga- nizes achievement. Membership dues for 2006, Regular Member- nization of the American Society of Anesthesiolo- ship is $100 annually; Student/Resident membership is free. Add gists. Membership dues for 2006 are $175 which Anesthesia and Analgesia for only $85. All STA correspondence include a reduced-rate subscription to ANESTHESIA & ANAL- should be sent to: STA, Attn: Jackie Dzurilla-Cencer, 2 Summit GESIA. Residents/Fellows: see Joint Resident/Fellow Membership infor- Park Drive, Suite 140, Cleveland, OH 44131. Telephone (216) mation below. All SCA membership payments and correspon- 447-7864; Fax (216) 642-1127; e-mail: [email protected]; Web dence should be sent to: SCA, 2209 Dickens Road, P.O. Box site: www.AnesTech.org 11086, Richmond, Virginia 23230-1086. Telephone (804) 282-0084; Fax (804) 282-0090; e-mail: [email protected]; Web site: ww- w.scahq.org JOINT RESIDENT/FELLOW MEMBERSHIP: Residents/Fellows in training will benefit from a reduced-rate Joint Resident/Fellow SOCIETY FOR PEDIATRIC ANESTHESIA (SPA) Membership in IARS/SCA/SPA/SAMBA/ISAP/STA. 2006 Dues is a nonprofit organization and is a recognized are $75 and include a subscription to ANESTHESIA & ANAL- subspecialty organization of the American Society GESIA plus a number of additional benefits. Joint Resident/ of Anesthesiologists. Membership dues for 2006 are Fellow Membership payments and inquiries should be di- $125 for active and affiliate membership, $50 for rected to the IARS at the address shown above. international membership. Residents/Fellows: see Joint Resident/ Fellow Membership information below. All SPA membership pay- JOINT MEMBERSHIP: Qualifying individuals will benefit from ments and correspondence should be sent to: SPA, 2209 Dickens a reduced-rate Joint IARS/SCA Membership for $210 that in- Road, P.O. Box 11086, Richmond, VA 23230-1086. Telephone cludes a subscription to ANESTHESIA & ANALGESIA. Joint (804) 282-9780; Fax (804) 282-0090; e-mail: [email protected]; IARS/SCA membership payments and inquiries should be di- Web site: www.pedsanesthesia.org rected to the SCA at the address shown above. SOCIETY FOR AMBULATORY ANESTHESIA (SAMBA) is a nonprofit organization and is a rec- NON-MEMBER SUBSCRIPTION INFORMATION: ognized subspecialty organization of the American Society of Anesthesiologists. Membership dues for 2006 SUBSCRIPTION RATES: U.S. Personal $446; Institutional 2006 are $150 for active, affiliate and international $648; Outside the U.S., add $120, except Japan. Single copy $64. membership, or $235 which includes a subscription to ANESTHE- Special in-training rate of $209 ($311 outside the U.S.) is available SIA & ANALGESIA. Residents/Fellows: see Joint Resident/Fellow to residents, interns and students for a period of three years. In Membership information below. All SAMBA membership pay- requesting this rate, please indicate training status and name of ments and correspondence should be sent to: SAMBA, 520 N. institution. This special in-training rate can be extended to all par- Northwest Highway, Park Ridge, Illinois 60068-2573. Telephone ticipants in four-year training programs, provided that sufficient
Load more

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • A Framework for Assurance of Medication Safety Using Machine Learning
    A Framework for Assurance of Medication Safety using Machine Learning Yan Jia1 Tom Lawton2 John McDermid1 Eric Rojas3 Ibrahim Habli1 Abstract— Medication errors continue to be the leading cause of avoidable patient harm in hospitals. This paper sets out a framework to assure medication safety that combines machine learning and safety engineering methods. It uses safety analysis to proactively identify potential causes of medication error, based on expert opinion. As healthcare is now data rich, it is possible to augment safety analysis with machine learning to discover actual causes of medication error from the data, and to identify where they deviate from what was predicted in the safety analysis. Combining these two views has the potential to enable the risk of medication errors to be managed proactively and dynamically. We apply the framework to a case study involving thoracic surgery, e.g. oesophagectomy, where errors in giving beta-blockers can be critical to control atrial fibrillation. This case study combines a HAZOP-based safety analysis method known as SHARD with Bayesian network structure learning and process mining to produce the analysis results, showing the potential of the framework for ensuring patient safety, and for transforming the way that safety is managed in complex healthcare environments. Keywords—medication safety, machine learning, proactive safety management 1. INTRODUCTION Safety analysis is both predictive and reactive. It aims to identify hazards, hazard causes and mitigations, and associated risks before a system is deployed. The system is then monitored during its deployment to manage risks. When systems are used in highly controlled environments, built using components with a long service history, these predictions can be accurate.
    [Show full text]
  • Supplementary Table 1 the Identified Bis-Probe Captured Enzymes After Liquid Chromatography-Tandem Mass Spectrometry Analysis of Adscs Treated with BME
    Supplementary Table 1 The identified Bis-probe captured enzymes after liquid chromatography-tandem mass spectrometry analysis of ADSCs treated with BME. Protein names Accession Gene names Mass Length Gene ontology (biological process) Gene ontology (molecular function) Number (Da) Dolichyl-diphosphooligosaccharide-- P04843 RPN1 68,569 607 RNA binding [GO:0003723] cellular protein modification process protein glycosyltransferase subunit 1 [GO:0006464] protein N-linked glycosylation [GO:0006487] protein N-linked glycosylation via asparagine [GO:0018279] Ras-related protein Rab-21 Q9UL25 RAB21 24,348 225 GDP binding [GO:0019003]; GTPase anterograde axonal transport KIAA0118 activity [GO:0003924]; GTP binding [GO:0008089] [GO:0005525] regulation of axon extension [GO:0030516] E3 ubiquitin/ISG15 ligase TRIM25 Q14258 TRIM25 EFP 70,973 630 interferon-gamma-mediated signaling cadherin binding [GO:0045296]; ligase RNF147 pathway [GO:0060333] activity [GO:0016874]; metal ion binding ZNF147 [GO:0046872]; RIG-I binding [GO:0039552]; RNA binding [GO:0003723]; ubiquitin protein ligase activity [GO:0061630] D-3-phosphoglycerate O43175 PHGDH 56,651 533 electron transfer activity [GO:0009055]; brain development [GO:0007420] dehydrogenase PGDH3 L-malate dehydrogenase activity glial cell development [GO:0021782] [GO:0030060]; NAD binding neural tube development [GO:0021915] [GO:0051287]; phosphoglycerate neuron projection development dehydrogenase activity [GO:0004617] [GO:0031175] Cdc42 effector protein 1 Q00587 CDC42EP1 40,295 391 positive regulation of
    [Show full text]
  • Abstracts of Posters Presented at the 2011 Annual Meeting of the International Anesthesia Research Society Vancouver, British Columbia, Canada May 21-24, 2011
    www.anesthesia-analgesia.org May 2011 • Volume 112 • Number 5 Final Supplement to Abstracts of Posters presented at the 2011 Annual Meeting of the International Anesthesia Research Society Vancouver, British Columbia, Canada May 21-24, 2011 This Supplement Will Appear Online Only 100 Pine Street, Suite 230 IARS San Francisco, CA 94111-5104 International Anesthesia Phone: 415-296-6900 • Fax: 415-296-6901 Research Society email: [email protected] • www.iars.org Publisher of ANESTHESIA & ANALGESIA IARSMISSION The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia-related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly Anesthesia & Analgesia journal. IARSBOARDOFTRUSTEES JAMES G. RAMSAY DENISE J. WEDEL ALEX EVERS CHAIR JOURNAL LIAISON BOARD MEMBER Atlanta, Georgia Rochester, Minnesota St. Louis, Missouri ROBERT N. SLADEN EMERY N. BROWN KEITH A. JONES PAST CHAIR BOARD MEMBER BOARD MEMBER New York, New York Boston, Massachusetts Birmingham, Alabama DEBRA A. SCHWINN JOHN F. BUTTERWORTH, IV COLLEEN G. KOCH TREASURER BOARD MEMBER BOARD MEMBER Seattle, Washington Indianapolis, Indiana Cleveland, Ohio HUGO VAN AKEN DAVY C. H. CHENG MAKOTO OZAKI SECRETARY BOARD MEMBER BOARD MEMBER Mu¨ nster, Germany London, Ontario, Canada Shinjuku, Tokyo, Japan IARSSTAFF THOMAS A.
    [Show full text]
  • Annual Report 2016
    Annexes to the annual report of the European Medicines Agency 2016 Annex 1 – Members of the Management Board ............................................................... 2 Annex 2 - Members of the Committee for Medicinal Products for Human Use ...................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ........................ 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ................. 8 Annex 5 – Members of the Committee on Orphan Medicinal Products .............................. 10 Annex 6 – Members of the Committee on Herbal Medicinal Products ................................ 12 Annex 7 – Committee for Advanced Therapies .............................................................. 14 Annex 8 – Members of the Paediatric Committee .......................................................... 16 Annex 9 – Working parties and working groups ............................................................ 18 Annex 10 – CHMP opinions: initial evaluations and extensions of therapeutic indication ..... 24 Annex 10a – Guidelines and concept papers adopted by CHMP in 2016 ............................ 25 Annex 11 – CVMP opinions in 2016 on medicinal products for veterinary use .................... 33 Annex 11a – 2016 CVMP opinions on extensions of indication for medicinal products for veterinary use .......................................................................................................... 39 Annex 11b – Guidelines and concept papers adopted by CVMP in 2016 ...........................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Mapping and Exome Sequencing Identifies a Mutation in the IARS Gene As the Cause of Hereditary Perinatal Weak Calf Syndrome
    Mapping and Exome Sequencing Identifies a Mutation in the IARS Gene as the Cause of Hereditary Perinatal Weak Calf Syndrome Takashi Hirano1,2*, Naohiko Kobayashi3, Tamako Matsuhashi3, Daisaku Watanabe4, Toshio Watanabe5, Akiko Takasuga5, Mayumi Sugimoto5, Yoshikazu Sugimoto1 1 Shirakawa Institute of Animal Genetics, Fukushima, Japan, 2 Laboratory of Animal Physiology, Faculty of Agriculture, Tokyo University of Agriculture, Kanagawa, Japan, 3 Hida Beef Cattle Research Department, Gifu Prefectural Livestock Research Institute, Gifu, Japan, 4 School of Veterinary Medicine and Animal Science, Kitasato University, Aomori, Japan, 5 National Livestock Breeding Center, Fukushima, Japan Abstract We identified an IARS (isoleucyl-tRNA synthetase) c.235G.C (p.Val79Leu) substitution as the causative mutation for neonatal weakness with intrauterine growth retardation (perinatal weak calf syndrome). In Japanese Black cattle, the syndrome was frequently found in calves sired by Bull A. Hence, we employed homozygosity mapping and linkage analysis. In order to identify the perinatal weak calf syndrome locus in a 4.04-Mb region of BTA 8, we analysed a paternal half-sibling family with a BovineSNP50 BeadChip and microsatellites. In this critical region, we performed exome sequencing to identify a causative mutation. Three variants were detected as possible candidates for causative mutations that were predicted to disrupt the protein function, including a G.C (p.Val79Leu) mutation in IARS c.235. The IARS c.235G.C mutation was not a homozygous risk allele in the 36 healthy offspring of Bull A. Moreover, the IARS Val79 residue and its flanking regions were evolutionarily and highly conserved. The IARS mutant (Leu79) had decreased aminoacylation activity. Additionally, the homozygous mutation was not found in any of 1526 healthy cattle.
    [Show full text]
  • Aminoacyl-Trna Synthetase Deficiencies in Search of Common Themes
    © American College of Medical Genetics and Genomics ARTICLE Aminoacyl-tRNA synthetase deficiencies in search of common themes Sabine A. Fuchs, MD, PhD1, Imre F. Schene, MD1, Gautam Kok, BSc1, Jurriaan M. Jansen, MSc1, Peter G. J. Nikkels, MD, PhD2, Koen L. I. van Gassen, PhD3, Suzanne W. J. Terheggen-Lagro, MD, PhD4, Saskia N. van der Crabben, MD, PhD5, Sanne E. Hoeks, MD6, Laetitia E. M. Niers, MD, PhD7, Nicole I. Wolf, MD, PhD8, Maaike C. de Vries, MD9, David A. Koolen, MD, PhD10, Roderick H. J. Houwen, MD, PhD11, Margot F. Mulder, MD, PhD12 and Peter M. van Hasselt, MD, PhD1 Purpose: Pathogenic variations in genes encoding aminoacyl- with unreported compound heterozygous pathogenic variations in tRNA synthetases (ARSs) are increasingly associated with human IARS, LARS, KARS, and QARS extended the common phenotype disease. Clinical features of autosomal recessive ARS deficiencies with lung disease, hypoalbuminemia, anemia, and renal tubulo- appear very diverse and without apparent logic. We searched for pathy. common clinical patterns to improve disease recognition, insight Conclusion: We propose a common clinical phenotype for recessive into pathophysiology, and clinical care. ARS deficiencies, resulting from insufficient aminoacylation activity Methods: Symptoms were analyzed in all patients with recessive to meet translational demand in specific organs or periods of life. ARS deficiencies reported in literature, supplemented with Assuming residual ARS activity, adequate protein/amino acid supply unreported patients evaluated in our hospital. seems essential instead of the traditional replacement of protein by Results: In literature, we identified 107 patients with AARS, glucose in patients with metabolic diseases. DARS, GARS, HARS, IARS, KARS, LARS, MARS, RARS, SARS, VARS, YARS, and QARS deficiencies.
    [Show full text]
  • Annexes to the Annual Report of the European Medicines Agency 2014
    Annexes to the annual report of the European Medicines Agency 2014 Table of contents Annex 1 – Members of the Management Board ............................................................................. 2 Annex 2 – Members of the Committee for Medicinal Products for Human Use ................................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ...................................... 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ............................... 8 Annex 5 – Members of the Committee on Orphan Medicinal Products ............................................ 10 Annex 6 – Members of the Committee on Herbal Medicinal Products .............................................. 12 Annex 07 – Committee for Advanced Therapies .......................................................................... 14 Annex 8 – Members of the Paediatric Committee ........................................................................ 16 Annex 9 – Working parties and working groups .......................................................................... 18 Annex 10 – CHMP opinions in 2014 on medicinal products for human use ...................................... 22 Annex 11 – CVMP opinions in 2014 on medicinal products for veterinary use .................................. 36 Annex 12 – COMP opinions in 2014 on designation of orphan medicinal products ............................ 41 Annex 13 – HMPC European Union herbal monographs in 2014....................................................
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Peri-Operative Medicine John Cohn
    Perioperative Medicine Steven L. Cohn (Editor) Perioperative Medicine Editor Steven L. Cohn Director – Medical Consultation Service Kings County Hospital Center Clinical Professor of Medicine SUNY Downstate Brooklyn, NY ISBN 978-0-85729-497-5 e-ISBN 978-0-85729-498-2 DOI 10.1007/978-0-85729-498-2 Springer London Dordrecht Heidelberg New York British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Control Number: 2011931531 © Springer-Verlag London Limited 2011 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permit- ted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licenses issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Preface Preoperative risk assessment and perioperative management are important aspects of clinical practice in internal medicine.
    [Show full text]
  • Safety and Efficacy of a Bolus Injection of Landiolol Hydrochloride As A
    Advance Publication by-J-STAGE Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Safety and Efficacy of a Bolus Injection of Landiolol Hydrochloride as a Premedication for Multidetector-Row Computed Tomography Coronary Angiography Kazuhiro Osawa, MD; Toru Miyoshi, MD; Shuhei Sato, MD; Noriaki Akagi; Yusuke Morimitsu; Kazufumi Nakamura, MD; Kunihisa Kohno, MD; Kengo Kusano, MD; Susumu Kanazawa, MD; Hiroshi Ito, MD Background: We evaluated the safety and efficacy of a bolus injection of landiolol hydrochloride, an ultrashort-act- ing β1-selective antagonist, as an additional treatment after premedication with an oral β-blocker to reduce heart rate prior to multidetector-row computed tomography (MDCT) coronary angiography (CAG). Methods and Results: A total of 458 patients who underwent MDCT CAG were retrospectively enrolled. Image quality and hemodynamic parameters were compared in patients before and after approval of landiolol hydrochloride. If heart rate reduction was insufficient after premedication with an oral β-blocker, a bolus injection of landiolol hydro- chloride (n=66) or other drugs (n=30) was used. The percentage of evaluable images per segment in patients after approval of landiolol (99.3%) was greater than that in patients before approval of landiolol (97.4%, P<0.01). Heart rates before scanning in patients receiving landiolol hydrochloride were similar to those receiving other drugs. Heart rate was significantly reduced approximately 5 min after injection of landiolol hydrochloride and increased shortly. No decrease in systolic blood pressure or other adverse effects was observed. Conclusions: Bolus injection of landiolol hydrochloride sufficiently reduced heart rate without significantly reducing systolic blood pressure and produced a high percentage of evaluable images, suggesting that bolus injection of landiolol hydrochloride as an additional pretreatment is feasible in MDCT CAG.
    [Show full text]